The role of dolutegravir in the management of HIV infection

Infection and Drug Resistance
Misty M MillerR Chris Rathbun

Abstract

Dolutegravir is the most recent integrase strand transfer inhibitor approved for HIV-1 infection in both treatment-naïve and experienced patients. As a tricyclic carbamoyl pyridone analog, dolutegravir is rapidly absorbed and distributes through the cerebrospinal fluid. It is hepatically metabolized by uridine diphosphate glucuronosyl transferase 1A1; no inhibition or induction of cytochrome P450 enzymes is noted. As a substrate of CYP 3A4, dolutegravir is affected by rifampin, efavirenz, tipranavir/ritonavir, fosamprenavir/ritonavir, and dose increase is required. Dolutegravir inhibits the organic cation transporter 2, resulting in decreased creatinine clearance with no apparent decrease in renal function. Other adverse effects are minimal but include diarrhea, headache, and nausea. Clinical trials in treatment-naïve and experienced patients are ongoing and will be presented in this text.

Citations

Nov 1, 2015·Expert Opinion on Drug Discovery·Fabrice Bailly, Philippe Cotelle
Mar 28, 2017·Expert Opinion on Pharmacotherapy·Helena RabieH Simon Schaaf
Sep 1, 2015·World Journal of Biological Chemistry·Duane P GrandgenettHideki Aihara

❮ Previous
Next ❯

Software Mentioned

VIKING

Related Concepts

Related Feeds

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Related Papers

Xenobiotica; the Fate of Foreign Compounds in Biological Systems
O PelkonenH Raunio
Therapeutics and Clinical Risk Management
Zelalem Temesgen, Dawd S Siraj
© 2022 Meta ULC. All rights reserved